Aicardi-Goutières Syndrome (AGS) Clinical Trial
Official title:
A Phase 2a Study of TPN-101 in Patients With Aicardi-Goutières Syndrome (AGS)
A phase 2a multi-center, open-label single dose level study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
The study is planned in pediatric and adult patients with AGS that are greater than 1 year and weigh at least 10 kg. The TPN-101 dose will be adjusted from 100 mg to 400 mg based on weight to achieve similar drug exposures in all subjects. The study plans to enroll 10 - 16 subjects. This study includes a 6-8 week Screening Period, a 48-week Open label Treatment Period, and a 12-week Follow-up Period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02363452 -
Reverse Transcriptase Inhibitors in AGS
|
Phase 2 | |
| No longer available |
NCT01724580 -
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
|